Evidence map›Paper›PMID 35920185›Full record

ArticleOncology reports2022

Synergistic effects of thalidomide and cisplatin are mediated via the PI3K/AKT and JAK1/STAT3 signaling pathways in cervical cancer.

Cairu Liu, Haiqin Feng, Lihong Song, Shuirui Li, Yiping Wu, Liping Yang

Open access · hybridAbstract read
In one paragraph

Article in Oncology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Network-based drug repurposing for HPV-associated cervical cancer.Computational and structural biotechnology journal · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Cairu LiuDepartment of Gynecology and Obstetrics, HanDan Central Hospital, Handan, Hebei 056008, P.R. China.
Haiqin FengDepartment of Gynecology and Obstetrics, HanDan Central Hospital, Handan, Hebei 056008, P.R. China.
Lihong SongDepartment of Gynecology and Obstetrics, HanDan Central Hospital, Handan, Hebei 056008, P.R. China.
Shuirui LiDepartment of Gynecology and Obstetrics, HanDan Central Hospital, Handan, Hebei 056008, P.R. China.
Yiping WuDepartment of Gynecology and Obstetrics, HanDan Central Hospital, Handan, Hebei 056008, P.R. China.
Liping YangDepartment of Gynecology and Obstetrics, HanDan Central Hospital, Handan, Hebei 056008, P.R. China.
Handan College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thalidomide (THD) has been found to synergize with cisplatin (DDP) in certain types of cancers; however, their combined use in the treatment of cervical cancer has not been reported to date, at least to the best of our knowledge. Thus, the present study aimed to explore the synergistic effects of THD and DDP and determine their regulatory effects on the phosphoinositide 3‑kinase (PI3K)/protein kinase B (AKT) and Janus kinase 1 (JAK1)/signal transducer and activator of transcription 3 (STAT3) pathways in cervical cancer. For this purpose, 0‑160 µM THD and 0‑64 µM DDP monotherapy or in combination were used to treat the HeLa and SiHa cervical cancer cell lines. This was followed by the calculation of the combination index (CI) and 160 µM THD and 16 µM DDP were then used to treat the cells. Relative cell viability and apoptosis, as well as the mRNA and protein levels of PI3K, AKT, JAK1 and STAT3 were evaluated. The results revealed that THD and DDP monotherapy suppressed the viability of the HeLa and SiHa cells in a concentration‑dependent manner. Moreover, THD and DDP treatment exerted a more prominent suppressive effect on the relative viability of HeLa and SiHa cells compared with DDP monotherapy at several concentration settings; further CI calculation revealed that the optimal synergistic concentrations were 160 µM for THD and 16 µM for DDP. Subsequently, combined treatment with THD and DDP suppressed relative cell viability, whereas it promoted cell apoptosis compared with THD or DPP monotherapy; it also inhibited the PI3K/AKT and JAK1/STAT3 signaling pathways compared with DPP or THD monotherapy in both HeLa and SiHa cells. On the whole, the present study demonstrated that THD synergizes with DDP to exert suppressive effects on cervical cancer cell lines. This synergistic action also inactivated the PI3K/AKT and JAK1/STAT3 pathways. Thus, these findings suggest that the combined use of THD and DPP may have potential for use in the treatment of cervical cancer.

Indexed as

CisplatinThalidomideUterine Cervical NeoplasmsDrug SynergismFemaleHumansJanus Kinase 1Phosphatidylinositol 3-KinasePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionSTAT3 Transcription FactorCisplatinJAK1 protein, humanJanus Kinase 1Phosphatidylinositol 3-KinasePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSTAT3 protein, humanSTAT3 Transcription FactorThalidomidecervical cancercisplatinJAK1/STAT3PI3K/AKTthalidomide

Identifiers

PMID35920185
PMCPMC9478987
OpenAlexW4289523274

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.